Breast Cancer : Basic and Clinical Research最新文献

{"title":"Rapid Hemostasis and Significant Tumor Regression in Ulcerative Breast Cancer Via Combined Modified Lattice Radiotherapy and Systemic Therapy: A Case Report.","authors":"Weiwei Sang, Yanyan Shi, Bin Wang, Lihua Zhang","doi":"10.1177/11782234261441378","DOIUrl":"https://doi.org/10.1177/11782234261441378","url":null,"abstract":"<p><p>Ulcerative giant breast cancer (UGBC) presents management challenges including uncontrolled bleeding, infection, and rapid tumor progression, which often culminate in life-threatening complications. Traditional spatially fractionated radiotherapy (SFRT) like lattice radiotherapy (LRT) offers potential for palliating bulky tumors, although its application in UGBC remains limited. We report a 51-year-old woman with a hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative stage IIIC UGBC (20.5 cm × 6.98 × 18.17 cm ulcerative lesion). Treatment consisted of modified lattice radiotherapy (mLRT: 15 Gy×3 fractions), followed by volumetric-modulated arc therapy (VMAT: 36 Gy/20 fractions) and systemic therapy (exemestane, capecitabine, CDK4/6 inhibitor). Rapid hemostasis was achieved within 5 days, with 39.7% tumor reduction at week 4 and progressive wound healing. At 3-month follow-up after the completion of mLRT and prior to definitive radiotherapy, the tumor had achieved a 61.8% volume reduction, with only minimal residual disease remaining. The radiation-induced skin reaction gradually alleviated with symptomatic treatment. This case demonstrates mLRT's efficacy in achieving rapid hemostasis and significant tumor regression for chemotherapy-refusing UGBC patients. The combined approach of mLRT, VMAT, and systemic therapy provides a promising multidisciplinary strategy for symptom control and quality-of-life improvement. Further prospective studies are needed to validate these findings.</p>","PeriodicalId":9163,"journal":{"name":"Breast Cancer : Basic and Clinical Research","volume":"20 ","pages":"11782234261441378"},"PeriodicalIF":1.9,"publicationDate":"2026-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13133437/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147811143","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Genes From Epithelial-Mesenchymal Transition Predict Overall Survival Effectively in Breast Cancer: A Novel Risk Model Based on Initial Step of Tumor Metastasis.","authors":"Wei Liang, Zi-Ying Wang, Quan-Feng Shao, Yuan-Yuan Li, Bei Zhu, Xi-Hu Qin, Wei-Xian Chen","doi":"10.1177/11782234261433697","DOIUrl":"https://doi.org/10.1177/11782234261433697","url":null,"abstract":"<p><strong>Background: </strong>Accumulating evidence has demonstrated that epithelial-mesenchymal transition (EMT) plays a critical role in breast cancer (BRCA) initiation, invasion, metastasis, and prognosis.</p><p><strong>Objectives: </strong>To develop and validate a comprehensive EMT-related gene signature for robust prognosis prediction in BRCA.</p><p><strong>Design: </strong>Retrospective multi-cohort study.</p><p><strong>Methods: </strong>We obtained 1223 BRCA samples from The Cancer Genome Atlas (TCGA) and 1184 EMT-related genes from the dbEMT2.0 public database. Prognostic genes were selected via univariate Cox and LASSO regression analyses to construct a risk score model, which was subsequently validated in independent internal cohort (TCGA) and external cohorts (UCSC and GEO). Finally, a nomogram integrating the risk score with clinical parameters was established.</p><p><strong>Results: </strong>A 15-gene EMT signature was identified and used to stratify patients into high- and low-risk groups. The high-risk group exhibited significantly poorer overall survival in the TCGA cohort (<i>P</i> < .05), a finding consistently validated across 4 independent datasets (all <i>P</i> < .05). The risk score served as an independent prognostic factor (hazard ratio = 2.386, <i>P</i> < .001). The integrative nomogram, incorporating the risk score, age, and N and M stages, demonstrated moderate accuracy for survival prediction (C-index = 0.711).</p><p><strong>Conclusions: </strong>We developed and validated a novel 15-gene EMT signature and a corresponding nomogram, which provide a potential tool for prognostic stratification in BRCA patients.</p>","PeriodicalId":9163,"journal":{"name":"Breast Cancer : Basic and Clinical Research","volume":"20 ","pages":"11782234261433697"},"PeriodicalIF":1.9,"publicationDate":"2026-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13051166/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147632311","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Clinical Presentation, Management, and Outcomes of Breast Adenomyoepithelioma: A Single-Institution Experience.","authors":"Lyndsay Cooper, Saheli Parekh, Korene Gbozah, Patrick Wilson, Sean E Kisch, Dipika Misra, Kristina Shaffer","doi":"10.1177/11782234261431040","DOIUrl":"10.1177/11782234261431040","url":null,"abstract":"<p><strong>Background: </strong>Adenomyoepithelioma (AME) of the breast is a rare biphasic neoplasm characterized by proliferation of epithelial and myoepithelial cells. Although most AMEs demonstrate indolent behavior, malignant transformation has been reported, and diagnostic uncertainty often complicates clinical management. Given the rarity of AME, most data are limited to case reports and small series, leaving optimal management undefined.</p><p><strong>Objectives: </strong>To describe the clinical presentation, imaging characteristics, histopathologic features, and outcomes of patients with breast AME.</p><p><strong>Design: </strong>Retrospective single-institution case series.</p><p><strong>Methods: </strong>We retrospectively reviewed 15 patients diagnosed with breast AME between 2010 and 2023. Demographic, clinical, imaging, core needle biopsy (CNB) findings, surgical pathology, and outcomes data were analyzed.</p><p><strong>Results: </strong>The median age at diagnosis was 56 years. More than half of the patients (53.3%) were asymptomatic at presentation. Mammography most frequently demonstrated discrete ovoid masses (61.5%), and ultrasound most often showed hypoechoic lesions (66.7%) with lobulated margins (50%). Core needle biopsy identified benign AME in 38.4% of cases, while 61.5% yielded indeterminate findings with AME included in the differential. Five patients underwent CNB alone without surgical excision. Of the 9 patients who underwent both CNB and excision, 6 (66.7%) had AME on final pathology, whereas 3 were upgraded (2 invasive carcinoma, 1 atypical ductal hyperplasia). Of the 3 cases with cytologic atypia on CNB, 1 was upgraded to invasive carcinoma. Over a median follow-up of 10 months, no recurrences, metastases, or breast cancer-related deaths were observed.</p><p><strong>Conclusions: </strong>Breast AME generally follows a benign clinical course, but diagnostic challenges exist due to histologic heterogeneity. Core needle biopsy features such as cytologic atypia may indicate higher malignancy risk. These findings highlight the ongoing dilemma of when observation is sufficient versus when surgical excision is warranted. Our results add to the limited body of evidence and align with prior reports, underscoring the need for larger, multicenter studies with longer follow-up to clarify long-term outcomes and optimal management strategies.</p>","PeriodicalId":9163,"journal":{"name":"Breast Cancer : Basic and Clinical Research","volume":"20 ","pages":"11782234261431040"},"PeriodicalIF":1.9,"publicationDate":"2026-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13018682/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147572540","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Zeste White 10 May Serve as a Prognostic Biomarker and Therapeutic Target for Human Breast Cancer.","authors":"Sm Faysal Bellah, Md Alim Hossen, Sm Saker Billah, Olanrewaju Ayodeji Durojaye, Md Obayed Raihan","doi":"10.1177/11782234261428784","DOIUrl":"https://doi.org/10.1177/11782234261428784","url":null,"abstract":"<p><strong>Background: </strong>Zeste White 10 (ZW10) is a key component of the spindle assembly checkpoint (SAC) that maintains chromosomal stability during mitosis. Dysregulation of ZW10 can cause chromosomal instability and aneuploidy-hallmarks of many cancers, including breast cancer, particularly triple-negative breast cancer (TNBC). However, its prognostic and therapeutic relevance in breast cancer remains unclear.</p><p><strong>Objectives: </strong>This study aimed to systematically investigate the expression pattern, prognostic significance, mutational profile, and immune associations of ZW10 in breast cancer using integrated omics data.</p><p><strong>Design: </strong>A computational, cross-cohort bioinformatics analysis combining transcriptomic, proteomic, mutational, and clinical data from publicly available databases.</p><p><strong>Methods: </strong>The ZW10 expression levels were assessed across normal and cancerous tissues using The Cancer Genome Atlas (TCGA), Genotype-Tissue Expression (GTEx), and the Human Protein Atlas data sets. Immune infiltration correlations were analyzed using TIMER2.0, Gene Set Cancer Analysis (GSCA), and TNMplot. Survival analyses were performed using Kaplan-Meier Plotter and TCGA clinical data sets. Protein-protein interaction (PPI) and functional enrichment analyses were conducted using STRING and EnrichR, and mutation data were retrieved from COSMIC and cBioPortal.</p><p><strong>Results: </strong>The ZW10 expression was markedly upregulated across multiple cancers, with the highest expression in TNBC. Elevated ZW10 levels correlated with immune cell infiltration and adverse overall survival, while lower ZW10 expression predicted improved relapse-free survival. Protein-protein interaction and enrichment analyses revealed ZW10's close interaction with key mitotic regulators and its involvement in spindle checkpoint and vesicular trafficking pathways. Mutation analysis identified predominant A > G and A > T substitutions and frequent gene amplifications across malignancies.</p><p><strong>Conclusion: </strong>The ZW10 acts as a potential prognostic biomarker and therapeutic target in breast cancer, particularly TNBC, through its dual roles in mitotic regulation and immune modulation. Further experimental validation is warranted to confirm its mechanistic role and therapeutic potential.</p>","PeriodicalId":9163,"journal":{"name":"Breast Cancer : Basic and Clinical Research","volume":"20 ","pages":"11782234261428784"},"PeriodicalIF":1.9,"publicationDate":"2026-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12979883/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147466187","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identification of Genetic Variants Among Breast Cancer Patients and At-Risk Individuals: A Cohort Study in Sri Lanka.","authors":"Lalani Yatawara, Badra Hewavithana, Ashansa P Ramanayake, Susiji Wickramasinghe, Malithi Amarasiri","doi":"10.1177/11782234261420605","DOIUrl":"https://doi.org/10.1177/11782234261420605","url":null,"abstract":"<p><strong>Background: </strong>Breast cancer remains a major global health challenge, as it is the most commonly diagnosed malignancy worldwide, particularly among women. Germline variants in cancer-predisposing genes play a critical role in breast cancers with familial origin.</p><p><strong>Objectives: </strong>To identify genetic variants in cancer-predisposing genes among breast cancer patients and individuals at risk in a selected cohort from two imaging facilities in the Central Province of Sri Lanka.</p><p><strong>Design: </strong>A genetic association study involving breast cancer confirmed patients, at-risk individuals, and healthy controls.</p><p><strong>Methods: </strong>Blood samples were collected from consenting patients, and genomic DNA was extracted from the samples and subjected to Next Generation Sequencing and Sanger sequencing. The inherited predisposition to breast cancer was evaluated to find genes associated with breast cancer using the Ion Torrent PGM platform followed by bioinformatics analysis.</p><p><strong>Results: </strong>Variants were detected in several high- and moderate-penetrance genes, including <i>BRCA1</i> [c.3113A>G; p.Glu1038Gly], <i>BRCA2</i> [c.6509A>G; p.Lys2170Arg; c.7879A>T; p.Ile2627Phe; c.5574_5577delAATT; p.Ile1859LysfsTer3], <i>PALB2</i> [c.1592delT; p.Leu531fs], <i>BRIP1</i> [c.2400C>T;], and in <i>MRE11A</i> [c.508C>A; p.Gln170Lys] genes. Among these, <i>BRCA2</i> mutations and the <i>PALB2</i> frameshift deletion were classified as pathogenic germline variants. The benign <i>BRCA1</i> variant [c.3113A>G; p.Glu1038Gly] was the most frequent variant observed. Common missense variants included <i>BRCA1</i> [c.3113A>G; p.Glu1038Gly; c.3548A>G; p.Lys1183Arg; c.2612C>T; p.Pro871Leu], <i>BRCA2</i> [c.7397T>C; p.Val2466Ala], and <i>ATM</i> [c.5948A>G; p.Asn1983Ser], while frequently detected intronic variants were found in <i>MUTYH</i> [c.1468-40C>G;], <i>PALB2</i> [c.3114-51T>A;], and <i>NF1</i> [c.288+41G>A; c.328+37C>G;]. Pathogenic variants occurred in fewer than 10% of individuals in any group, and other variants were identified in different frequencies. <b>Conclusion:</b> Evaluation of germline variants in this cohort revealed the presence of pathogenic mutations and other variants with benign or uncertain significance. Three pathogenic variants, <i>BRCA2</i> [c.6509A>G; c.7879A>T; c.5574_5577delAATT] and <i>PALB2</i> [c.1592delT], were identified in high-risk genes important for breast cancer prediction. Identification of population-based variants may improve breast cancer screening and management in Sri Lanka.</p>","PeriodicalId":9163,"journal":{"name":"Breast Cancer : Basic and Clinical Research","volume":"20 ","pages":"11782234261420605"},"PeriodicalIF":1.9,"publicationDate":"2026-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12954010/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147353838","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Perceptions of Breast Cancer: A Cross-Sectional Study Using the Breast Cancer Perception Scale (BPS).","authors":"Omer Kheir, Nada Baatiah, Anwar Alotaibi, Sheikha Dossary, Mohammad Dhalaan, Hayat AlMushcab, Mariam Al Romaihi, Maryam Al Darweesh, Rasiel Kabli, Mohammad Ghamdi","doi":"10.1177/11782234251410402","DOIUrl":"https://doi.org/10.1177/11782234251410402","url":null,"abstract":"<p><strong>Background: </strong>Breast cancer is the most common malignancy among Saudi women, and early detection remains a critical factor for improving survival outcomes. Despite ongoing awareness initiatives, screening uptake remains low, suggesting that perceptions and beliefs may influence women's engagement in preventive behaviors.</p><p><strong>Objectives: </strong>To assess perceptions of breast cancer among women attending Johns Hopkins Aramco Healthcare (JHAH) facilities using the Breast Cancer Perception Scale (BPS) and to examine associations between perception domains and sociodemographic as well as screening-related factors.</p><p><strong>Design: </strong>A cross-sectional, questionnaire-based study was conducted between October 2024 and March 2025.</p><p><strong>Methods: </strong>Eligible female patients aged 20 years or older with active MyChart accounts were invited to participate electronically. Perception was measured using the validated 24-item BPS, which comprises 6 subscales. Due to non-normal data distribution, non-parametric tests (Kruskal-Wallis and Mann-Whitney U) were employed, with a Bonferroni correction for multiple comparisons.</p><p><strong>Results: </strong>Participants had a mean age of 37.5 ± 8.3 years, and 61.4% held a university degree. Postgraduate education was significantly associated with higher scores for Perceived Knowledge, Treatment Belief, Health Check, and Risk, as well as lower stigma (<i>P</i> < .001). Employed women demonstrated greater Perceived Knowledge (<i>P</i> < .001). Those with a family history of breast cancer reported higher Fear and Risk perceptions (<i>P</i> < .001). Prior screening experience (clinical breast examination or Mammography) correlated with higher Knowledge and Health Check perceptions and lower stigma (<i>P</i> < .001). Overall, 51.7% of participants reported adequate knowledge, while 64% to 70% expressed moderate to high levels of fear.</p><p><strong>Conclusion: </strong>Perceptions of breast cancer among Saudi women are shaped by educational level, employment status, family history, and screening experience. Targeted educational interventions that address knowledge gaps and cultural stigmas are essential for enhancing participation in screening and early detection practices.</p>","PeriodicalId":9163,"journal":{"name":"Breast Cancer : Basic and Clinical Research","volume":"20 ","pages":"11782234251410402"},"PeriodicalIF":1.9,"publicationDate":"2026-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12831882/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146050377","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative Analysis of Equivocal (2+) and Positive (3+) HER2 Immunohistochemistry (IHC) and Bright-Field Dual-Color In Situ Hybridization (DISH) in Primary Breast Cancer From 1,307 Node-Positive Patients.","authors":"Kroonpong Iampenkhae, Adiluck Pisutpunya, Chawinthorn Vuthithammee, Piyakawin Sodsoon, Sompon Apornvirat","doi":"10.1177/11782234251407914","DOIUrl":"10.1177/11782234251407914","url":null,"abstract":"<p><strong>Background: </strong>Human epidermal growth factor receptor 2 (HER2) is an important predictive and prognostic biomarker in breast cancer. Immunohistochemistry (IHC) is the preferred initial test due to its cost-effectiveness and simplicity. While fluorescence in situ hybridization (FISH) is the traditional gold standard test for HER2 gene amplification, DISH has emerged as an accepted alternative that allows evaluation under a standard light microscope.</p><p><strong>Objectives: </strong>To evaluate agreement between HER2 IHC (2+/3+) and DISH in node-positive primary breast cancers and compare findings with published IHC and FISH data.</p><p><strong>Design: </strong>Retrospective single-center cohort study using nationwide referral specimens.</p><p><strong>Methods: </strong>Cases of pathologically confirmed lymph node metastasized invasive breast carcinoma with HER2 IHC scores of 2+ and 3+ were retrieved. Interpretation of HER2 IHC was performed using the 2023 ASCO/CAP guideline. HER2 DISH was conducted and evaluated by the HER2/CEP17 signal ratio on primary tumors first, and on metastasized lymph nodes in cases of persistent technical failure.</p><p><strong>Results: </strong>Among 1,307 breast cancers, DISH detected HER2 amplification in 933 cases, including 92% (760) of IHC 3+ cases and 36% (173) of IHC 2+ cases. Seven cases with persistent technical failure on primary tumors were resolved when switching to lymph node specimens. Comparison with the meta-analysis data of IHC and FISH showed no significant differences, indicating that DISH is a reliable alternative to FISH.</p><p><strong>Conclusion: </strong>Our study demonstrates a high concordant rate between HER2 IHC and DISH in the IHC 3+ group and a low positive rate in the IHC 2+ group. We found no significant difference in the positive rates of HER2 IHC to DISH when compared with prior data of IHC to FISH, reaffirming the use of HER2 DISH as an effective and more accessible alternative to FISH in HER2 2+/3+ breast cancer.</p>","PeriodicalId":9163,"journal":{"name":"Breast Cancer : Basic and Clinical Research","volume":"19 ","pages":"11782234251407914"},"PeriodicalIF":1.9,"publicationDate":"2025-12-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12754044/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145888575","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical and Pathological Characteristics and Treatment Implications of <i>BRCA1</i>- and <i>BRCA2</i>-Mutated Breast Cancer in Japanese Patients: A Single-Institution Retrospective Study.","authors":"Yumiko Akita, Madoka Iwase, Toyone Kikumori, Dai Takeuchi, Yuko Takano, Takahiro Ichikawa, Norikazu Masuda","doi":"10.1177/11782234251399355","DOIUrl":"10.1177/11782234251399355","url":null,"abstract":"<p><strong>Background: </strong>Although <i>BRCA1</i> and <i>BRCA2</i> mutations are known to be associated with different breast cancer (BC) subtypes, real-world evidence on how these genetic differences influence tumor behavior and treatment decisions remains limited, particularly in Japanese patients. With the recent expansion of PARP inhibitor indications in Japan, <i>BRCA</i> testing has become increasingly routine, highlighting the need for clinical data tailored to local populations.</p><p><strong>Objectives: </strong>To compare clinicopathological features, recurrence patterns, and surgical choices between <i>BRCA1</i>- and <i>BRCA2</i>-associated BC in Japanese patients, with a focus on ER-positive tumors.</p><p><strong>Design: </strong>A single-institution retrospective cohort study.</p><p><strong>Methods: </strong>We retrospectively reviewed 417 patients who underwent <i>BRCA1/2</i> genetic testing at a single Japanese institution between April 2020 and November 2023. Of these, 38 patients (12 <i>BRCA1</i>, 26 <i>BRCA2</i>) had pathogenic variants. We compared clinicopathological features, recurrence patterns, and choices of risk-reducing surgery between <i>BRCA1</i> and <i>BRCA2</i> carriers.</p><p><strong>Results: </strong><i>BRCA1</i>-associated cancers were predominantly triple-negative (75%) and diagnosed at earlier stages (T1 in 83.3%), while <i>BRCA2</i>-associated cancers were mainly ER-positive (69.2%) and more likely to present with multiple lymph node metastases (⩾2 nodes in 42.3%). Although Ki-67 levels were higher in <i>BRCA1</i> tumors, this was largely subtype-dependent. Notably, ER-positive <i>BRCA</i> tumors showed a trend toward higher recurrence. Preferences for prophylactic surgery also varied by mutation type.</p><p><strong>Conclusion: </strong>This single-institution study highlights clinically meaningful differences between <i>BRCA1</i>- and <i>BRCA2</i>-associated BC in Japanese patients. <i>BRCA2</i> cancers tended to present with more advanced features, while <i>BRCA1</i> cancers were more often detected at earlier stage. These findings underscore the value of <i>BRCA</i> testing not only for PARP inhibitor eligibility but also for subtype-specific risk assessment and individualized preventive strategies.</p>","PeriodicalId":9163,"journal":{"name":"Breast Cancer : Basic and Clinical Research","volume":"19 ","pages":"11782234251399355"},"PeriodicalIF":1.9,"publicationDate":"2025-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12701933/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145761597","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Nationally Representative US Health and Retirement Study on Mammography Screening Use and Its Predictors Among Older Adult Women Ages 60 to 85.","authors":"Angela Sy, Merle Kataoka-Yahiro, James Davis, Sarah Pirani, Yumiko Kinoshita, Nahoko Harada, Maki Kanaoka, Mami Miyazono","doi":"10.1177/11782234251392690","DOIUrl":"10.1177/11782234251392690","url":null,"abstract":"<p><strong>Background: </strong>Mammography use and its predictors among older women require further study.</p><p><strong>Objectives: </strong>Mammography use and its relationship to demographic characteristics, health care access, and breast cancer risk factors in women ages 60 to 85 in the United States were examined.</p><p><strong>Design: </strong>US Health and Retirement Study 2014 dataset was examined.</p><p><strong>Methods: </strong>A descriptive study using secondary data was analyzed for use of mammography screening and its predictors in women ages 60 to 85 in United States.</p><p><strong>Results: </strong>In total, 5177 (73.4%) of respondents reported mammography use. Mammography use was higher among older women who were married, nonsmokers, alcohol drinkers, engaged in vigorous exercise, and had dental visits.</p><p><strong>Conclusion: </strong>Women ages 60+ in the US HRS dataset revealed continued mammography screening into later years (73.4%), and mammography use was higher among older women who had healthy lifestyles and habits. Insights for health care providers and systems are to recommend mammography use for women age 60 to 85 years are provided. This US study can be used to inform future research and policy regarding breast cancer screening among older women.</p>","PeriodicalId":9163,"journal":{"name":"Breast Cancer : Basic and Clinical Research","volume":"19 ","pages":"11782234251392690"},"PeriodicalIF":1.9,"publicationDate":"2025-12-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12681626/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145707123","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Total Body PET/MRI as a Gold Standard for Staging Breast Cancer During Pregnancy in a Case Report.","authors":"Maher Salamoon, Heya Ahmad, Hanaa Ktyman, Dana Chaker","doi":"10.1177/11782234251396398","DOIUrl":"10.1177/11782234251396398","url":null,"abstract":"<p><p>Pregnancy-associated breast cancer (PABC) is the most prevalent invasive cancer in pregnant women, notably affecting those aged over 35 years. Postpartum cases exhibit a poorer prognosis than non-PABC women, while the prognosis of PABC is the same as that of non-PABC. Our case report presents a 25-year-old, 20th-week pregnant woman. Abdominal ultrasound revealed hepatic metastases; thus, total body PET/MRI without contrast exhibited two breast masses, bilateral axillary nodules, multiple hepatic metastases and osseous metastases in vertebral column, pelvis, and femoral bones. In conclusion, whole-body MRI (WB/MRI) and PET-MRI are important tools for diagnosing breast cancer in pregnant women and determining the stage of it.</p>","PeriodicalId":9163,"journal":{"name":"Breast Cancer : Basic and Clinical Research","volume":"19 ","pages":"11782234251396398"},"PeriodicalIF":1.9,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12669526/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145667024","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}